Fluicell

Fluicell Operating Expenses

The Total Operating Expenses of Fluicell (FLUI.ST) as of Nov 20, 2026 is 11.89 M SEK. In the previous year, Total Operating Expenses was 14.36 M SEK — a change of -17.16% (lower).

Operating Expenses

11.89 MSEK

YoY

-17.16%

Last updated:

Total Operating Expenses of Fluicell is 2025 11.89 M SEK. Total Operating Expenses of Fluicell was 2024 14.36 M SEK. It decreases by -17.16% lower compared to the previous year.

The Fluicell Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
7.43 M SEK
Jan 1, 2019
8.32 M SEK
Jan 1, 2020
7.13 M SEK
Jan 1, 2021
9.94 M SEK
Jan 1, 2022
16.87 M SEK
Jan 1, 2023
18.55 M SEK
Jan 1, 2024
14.36 M SEK
Jan 1, 2025
11.89 M SEK
The Fluicell Operating Expenses history
YEAROperating ExpensesYoY
11.89 MSEK-17.16%
14.36 MSEK-22.60%
18.55 MSEK+9.97%
16.87 MSEK+69.66%
9.94 MSEK+39.36%
7.13 MSEK-14.25%
8.32 MSEK+11.96%
7.43 MSEK+87.84%
3.96 MSEK-14.98%
4.65 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Total Operating Expenses of Fluicell is 11.89 M SEK in 2025.

Total Operating Expenses of Fluicell changed from 14.36 M SEK to 11.89 M SEK, representing a -17.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Fluicell since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Fluicell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Fluicell

All Key Metrics — Fluicell